ClinicalTrials.Veeva

Menu

Influence of a Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) on Embryonic Aneuploidy Rate and Developmental Potential

U

Universitair Ziekenhuis Brussel

Status and phase

Terminated
Phase 1

Conditions

Infertility

Treatments

Procedure: prematuration culture

Study type

Interventional

Funder types

Other

Identifiers

NCT00822874
IWT-JSMDV2008pilot

Details and patient eligibility

About

A single centre randomised controlled trial investigating the influence of a novel prematuration system (PMS) using a phosphodiesterase-3 inhibitor for in-vitro maturation of oocytes - pilot study.

Enrollment

115 patients

Sex

Female

Ages

18 to 35 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • healthy volunteers, either with PCOS/PCOS-like ovaries, or with normal ovaries, who undergo oocyte donation for research
  • AFC at least 10
  • AMH: > 5 μg/L
  • Female age < 36 years

Exclusion criteria

  • major uterine or ovarian abnormalities

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

115 participants in 1 patient group

in-vitro maturation of oocytes
Experimental group
Treatment:
Procedure: prematuration culture

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems